Drugs like minocycline and dexamethasone, which modulate glial activity, have shown potential benefits, while the NLRP3 inhibitor MCC950 has been demonstrated to reduce microglial activation and alleviate PD symptoms (258). This evidence concerns the gene NLRP3 and Parkinson disease.